drugset
drugset / Trial / NCT05093530

Safety and Tolerability of Single and Multiple Doses of Neumifil

NCT05093530 ↗

Phase 1 Completed 60 enrolled Pneumagen Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 1, single-centre, randomised, placebo-controlled first in human study in healthy subjects. The study will assess the safety and tolerability of single-ascending (Part A) and multiple-ascending (Part B) doses of Neumifil, administered intranasally.

Timeline

Start
2021-10-12
Primary completion
2022-04-05
Completion
2022-04-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Neumifil Unknown 0.028 mg Intranasal
Subject Neumifil Unknown 0.085 mg Intranasal
Subject Neumifil Unknown 0.28 mg Intranasal
Subject Neumifil Unknown 0.885 mg Intranasal
Subject Neumifil Unknown 2.8 mg Intranasal

Indications

viral respiratory tract infection